6-10 month-old infants viewed faces with dynamic eye gaze directed either towards them or away from them. Approximately 18 to 30 months later, these children were clinically evaluated for the presence of an ASD. Strikingly, neural responses to dynamic eye gaze shifts during the first year predicted clinical outcomes at 36 months, despite similar patterns of gaze as measured by eye tracking. The authors [4] conclude that ERP responses to eye gaze in the first year of life reflect developmental processes leading to the later emergence of ASD.
As the field strives for earlier methods of detecting autistic development, these remarkable findings offer hope for future clinical practice, suggesting the possibility of non-invasive, brain-based screening methods that could detect differences prior to behavioral emergence. ERPs are collected with the same technology (electroencephalography) commonly used in hospitals around the world for universal auditory screening of newborns; the infrastructure might already be in place to implement population-based screening in an affordable and highly efficient manner [5] . Of course, prior to realization of such clinical benefits, it will be critical to investigate the specificity of this biomarker to autism, its presence in an unselected, population-based sample, and, most importantly, its viability in individual patient data. Given historical difficulty parsing heterogeneity in ASD, these findings suggest the potential power of systems neuroscience approaches to identify meaningful subtypes of ASD to inform treatment and predicting outcome. We envision a strategy of deep behavior and brain phenotyping over longitudinal development to offer a detailed profile of brain-behavior performance for a given individual for the purpose of detection of atypical development, subcategorization (for example, for genetic analysis), treatment selection, and prediction of treatment response.
There is an important historical perspective to be noted here. Elsabbagh and colleagues [4] focused their analyses on the P1, N290 and P400 components of the ERP signal, components that are modulated in a number of face perception tasks, including tests of sensitivity to the direction of eye gaze in infants as young as four months [6] . Critically, experiments from a number of laboratories around the world have identified these ERP components in infants as precursors of the well-established face-sensitive N170 component in adults [7] . Just over sixteen years ago, in the Yale Neuropsychology Laboratory, Gregory McCarthy, Shlomo Bentin, and their colleagues first described the 'N170': while recording from scalp electrodes in typically developing adult volunteers, they discovered that human faces and face parts (especially the eyes) reliably evoked a negative ERP at 172 ms (range 130-200 ms) that they labeled the N170. This response was absent from the ERPs elicited by many other animate and inanimate non-face objects, and was maximal over occipitotemporal electrode sites. This work, coupled with numerous behavioral findings concerning face-processing deficits in ASD, led researchers (including an author of this dispatch) to study the N170 in children, adolescents, and adults with ASD [8] . This set of events, from the basic science discovery of a neural signature for face processing in the human brain to its translation into a potential biomarker for the emergence of ASD represents the very finest in the emerging field of translational developmental social neuroscience. Mitosis: Short-Circuiting Spindle Checkpoint Signaling
The spindle checkpoint forms an intricate signaling circuit to sense unattached kinetochores, to inhibit the anaphase-promoting complex/cyclosome (APC/C), and to delay anaphase onset. Using clever genetic experiments in the budding yeast, Lau and Murray define the endpoint of checkpoint signaling and provide key mechanistic insights into checkpoint inhibition of APC/C.
Xuelian Luo 1, * and Hongtao Yu 1,2, *
The spindle checkpoint is a cell-cycle surveillance system that guards against chromosome missegregation in mitosis and meiosis [1, 2] . Dysregulation of the spindle checkpoint can result in aneuploidy and cancer predisposition. The molecular dissection of this checkpoint began two decades ago with yeast genetic studies that identified Mad (mitotic arrest deficient) and Bub (budding uninhibited by benomyl) proteins as key checkpoint components [3, 4] . Subsequent genetic, biochemical, and structural studies in multiple organisms from yeast to man then delineated a general framework of how the spindle checkpoint operates [2, 5] .
In this framework, checkpoint proteins are recruited to kinetochores not properly attached to the mitotic spindle in a hierarchical fashion. At the top of this hierarchy are two checkpoint kinase complexes: the Aurora B-containing chromosome passenger complex and the Bub1-Bub3 complex. These kinases are required for the proper recruitment of Mad3/ BubR1-Bub3 (BubR1 is the vertebrate ortholog of Mad3) and Mps1, which in turn are required for recruiting Mad1-Mad2 and the checkpoint target Cdc20 to the kinetochores. At the kinetochores, Bub1 and Mps1 undergo phosphorylation-dependent enzymatic activation while Mad2 undergoes conformational activation. The activated checkpoint proteins promote the formation of the mitotic checkpoint complex (MCC) containing Mad3/BubR1, Bub3, Mad2, and Cdc20, which inhibits the activity of the multisubunit ubiquitin ligase APC/C. APC/C inhibition stabilizes its substrates cyclin B and the separase inhibitor securin, delaying anaphase onset.
A key unresolved issue in spindle checkpoint signaling is whether MCC formation is sufficient to inhibit APC/C in a physiological setting. Because MCC could be detected in interphase mammalian cells and in yeast cells lacking functional kinetochores [6, 7] , it has been proposed that an active spindle checkpoint might additionally modify MCC or APC/C or both in mitosis to endow the existing MCC with the ability to inhibit APC/C. Using clever genetic experiments in yeast, as reported in a recent issue of Current Biology, Lau and Murray [8] now show that MCC formation is the endpoint of checkpoint signaling. Forced formation of this complex or even a Mad2-Cdc20 sub-complex is sufficient to block APC/C activation in the absence of functional kinetochores or other upstream checkpoint proteins.
Lau and Murray began their study by testing the cellular effects of tethering Mad2 and Mad3 (two MCC subunits) either covalently through the construction of Mad2-Mad3 fusion proteins or non-covalently through fusing each to leucine zippers known to form heterodimers [8] . Both ways of tethering Mad2 and Mad3 in cells produced metaphase arrest, as evidenced by the accumulation of large-budded cells and the stabilization of the APC/C substrate Pds1 (the yeast securin). The metaphase arrest exerted by the Mad2-Mad3 fusion was still observed in cells deficient of the core kinetochore component Ndc10, suggesting that the cellular effects of the Mad2-Mad3 fusion were independent of functional kinetochores. The Mad2-Mad3 fusion also arrested at metaphase cells deleted of non-essential checkpoint proteins, including Mad1, Mad2, Mad3, Bub1, and Bub3. The metaphase arrest caused by the Mad2-Mad3 fusion did not require the kinase activity of the two essential checkpoint kinases Ipl1 (the yeast Aurora B) and Mps1, as chemical inhibition of Mps1 and Ipl1 did not affect Pds1 stabilization in cells expressing the Mad2-Mad3 fusion. These results strongly suggest that the Mad2-Mad3 fusion directly binds to Cdc20 and inhibits APC/C in cells. By inference, the forced formation of the Mad2-Mad3-Cdc20 complex in cells is sufficient to inhibit APC/C, in a way that is independent of upstream checkpoint signaling. As Mad3 forms a constitutive complex with Bub3, a fraction of the tethered Mad2-Mad3-Cdc20 complex likely contains Bub3 to form the intact MCC. Because the Mad2-Mad3 fusion still arrests Bub3-null cells at metaphase, Bub3 in this complex is not required for APC/C inhibition, consistent with previous in vitro biochemical studies [9] .
Lau and Murray went on to show that tethering Mad2 and Cdc20 with the heterodimerizing leucine zippers was sufficient to induce metaphase arrest [8] . When the Mad2-zipper protein was overexpressed (driven by the GAL1 promoter), this metaphase arrest was largely independent of Mad1, Mad2, Mad3, Bub1, and Bub3, and did not require the kinase activities of Mps1 or Ipl1. Tethering Mad3 and Cdc20 with the same approach did not produce metaphase arrest, although it remained to be tested whether tethering Mad3 and Cdc20 compromised the APC/C Cdc20 -inhibitory activity of Mad3 in vitro. This caveat notwithstanding, the sufficiency of the tethered Mad2-Cdc20 complex to produce metaphase arrest strongly suggests that binding of Mad2 to Cdc20 is a critical downstream event in checkpoint signaling. Deletion of Mad3 did, however, diminish the extent of metaphase arrest exerted by tethering Mad2 and Cdc20 when Mad2-zipper was overexpressed. If Mad2-zipper were to be expressed at a lower level with the native MAD2 promoter, the metaphase arrest caused by tethering Mad2 and Cdc20 might be more dependent on Mad3. Therefore, their results are consistent with the notion that Mad2 and Mad3 cooperatively inhibit APC/C Cdc20 . The underlying reason for the synergy between Mad2 and Mad3/ BubR1 in APC/C inhibition is not understood, but may stem from the different mechanisms used by the two proteins to inhibit APC/C (Figure 1 ). Mad3/BubR1 contains APC/C Cdc20 -binding motifs that are commonly found in APC/C substrates and competitively blocks substrate binding to APC/C Cdc20 [10] [11] [12] . The mechanism by which Mad2 inhibits APC/C Cdc20 is unclear, but it does not directly block substrate binding to Cdc20. Instead, Mad2 may alter the APC/C-binding mode of Cdc20 and anchor Cdc20 to a site on APC/C that is different from the catalytically functional Cdc20-binding site [13, 14] . The current evidence thus suggests that Mad3/BubR1 and Mad2 cooperatively inhibit APC/C Cdc20 by blocking substrate access and by sequestering Cdc20 in a catalytically compromised location on APC/C. Tethering Mad2 to Cdc20 might be sufficient to sequester Cdc20 away from the active site in a process that does not strictly require Mad3, thus inhibiting APC/C and producing metaphase arrest.
The Lau and Murray study [8] also sheds light on the mechanism of Mad2 conformational activation in cells. Mad2 is an unusual two-state protein with two native folds, termed open/N1-Mad2 (O-Mad2) or closed/N2-Mad2 (C-Mad2) [15, 16] . O-Mad2 in the cytosol is recruited to kinetochores through an O-C-Mad2 asymmetric dimerization event with the kinetochore-bound Mad1-C-Mad2 core complex and is converted to an active intermediate Mad2 (I-Mad2) conformer, which then binds Cdc20 to form the Cdc20-C-Mad2 complex (Figure 2) . Results from the tethering experiments by Lau and Murray support this Mad2 conformational activation model. It has been proposed that Cdc20-C-Mad2 can further recruit and activate O-Mad2 to form more copies of Cdc20-C-Mad2, thus propagating checkpoint signal away from the kinetochores [16] (Figure 2) . The Lau and Murray data are inconsistent with this notion of self-propagation by Cdc20-C-Mad2. They showed that expression of untagged Cdc20 driven by the native CDC20 promoter relieved the metaphase arrest induced by tethering Mad2 to Cdc20. If the Cdc20-bound C-Mad2 could further activate O-Mad2, the tethered Cdc20-C-Mad2 complex is expected to activate the endogenous O-Mad2 in the cell, leading to the inhibition of untagged Cdc20. The fact that expression of untagged Cdc20 overcomes the metaphase arrest induced by tethering Mad2 and Cdc20 thus argues against a role of self-propagation by Cdc20-C-Mad2 in checkpoint signaling.
In summary, by short-circuiting spindle checkpoint signaling with clever genetic manipulations in yeast, Lau and Murray have defined the endpoint of checkpoint signaling and provided key insights into APC/C inhibition by checkpoint proteins. This approach will be useful in analyzing the circuitry formed by upstream checkpoint components in yeast. The Mad2-Mad3 fusion and the tethered Mad2-Cdc20 complex may prove to be valuable tools for future biochemical and structural studies on APC/C-inhibitory checkpoint complexes. The kinetochore-bound Mad1-C-Mad2 core complex recruits cytosolic O-Mad2, converts it to the high-energy I-Mad2 conformer, and promotes the formation of the Cdc20-C-Mad2 complex. It has been suggested that Cdc20-bound C-Mad2 can further recruit and convert O-Mad2 to I-Mad2, which can then form more Cdc20-C-Mad2 complexes (see shaded box). This self-propagation of the Cdc20-C-Mad2 complex is not supported by the Lau and Murray study [8] , as a tethered Cdc20-C-Mad2 complex fails to induce untimely binding between the endogenous O-Mad2 and Cdc20 proteins in yeast cells.
